Zhong Yuejiao, Wei Qiang, Lu You, Tang Xiuliang, Wang Zhongqiu, Chen Lingxiang
Department of Medical Oncology, the Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
Department of Ultrasonography, the Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China.
J Thorac Dis. 2020 Oct;12(10):6016-6022. doi: 10.21037/jtd-20-2855.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC.
A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients.
The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00-5.95), 5.0 months (95% CI: 3.0-6.00) in 90 patients with adenocarcinoma, and 4.5 months (95% CI: 4.00-7.00) in 60 patients with squamous cell carcinoma (P=0.676). The PFS was 6.5 months (95% CI: 4.00-8.80) and 4.5 months (95% CI: 4.00-5.60) in the first-/second-line and ≥ third-line patients, respectively (P=0.315). Following the Eastern Cooperative Oncology Group performance status (ECOG PS) score, the median PFS of 95 patients with a PS score 0-1 was 5.5 months (95% CI: 4.50-6.50), and the median PFS of 55 patients with a PS score ntswas 4.0 months (95% CI: 3.00-5.00) (P=0.221). For the 49 patients in the combination group the median PFS was 7.0 months (95% CI: 4.00-9.00), while that of the 101 patients in the anlotinib-alone group was 4.0 months in (95% CI: 2.80-5.50) (P=0.010). In a separate analysis of the combination group, the median PFS of anlotinib combined with chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and immunotherapy was 5.5 months (95% CI: 4.00-9.00), 12.0 months (95% CI: 6.00-12.00), and 6.5 months (95% CI: 4.00-9.80), respectively (P=0.036).
Anlotinib exhibits good tolerance and performance in prolonging the PFS of patients and has considerable potential as a treatment for advanced NSCLC.
非小细胞肺癌（NSCLC）是最常见的肺癌类型，其发病率严重影响人类健康。本研究旨在评估安罗替尼治疗晚期NSCLC患者的疗效和安全性。
对150例接受安罗替尼治疗的晚期NSCLC患者进行回顾性研究，这些患者在疾病进展或因不良事件不耐受后停止治疗。以晚期NSCLC患者的无进展生存期（PFS）作为终点。应用Kaplan-Meier生存曲线评估安罗替尼治疗晚期NSCLC患者的短期疗效。
150例患者的整个队列的中位PFS为5.0个月（95%CI：4.00-5.95），90例腺癌患者为5.0个月（95%CI：3.0-6.00），60例鳞状细胞癌患者为4.5个月（95%CI：4.00-7.00）（P=0.676）。一线/二线和≥三线患者的PFS分别为6.5个月（95%CI：4.00-8.80）和4.5个月（95%CI：4.00-5.60）（P=0.315）。根据东部肿瘤协作组体能状态（ECOG PS）评分，95例PS评分为0-1的患者的中位PFS为5.5个月（95%CI：4.50-6.50），55例PS评分nts的患者的中位PFS为4.0个月（95%CI：3.00-5.00）（P=0.221）。联合组49例患者的中位PFS为7.0个月（95%CI：4.00-9.00），而安罗替尼单药组101例患者的中位PFS为4.0个月（95%CI：2.80-5.50）（P=0.010）。在联合组的单独分析中，安罗替尼联合化疗、表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和免疫治疗的中位PFS分别为5.5个月（95%CI：4.00-9.00）、12.0个月（95%CI：6.00-12.00）和6.5个月（95%CI：4.00-9.80）（P=0.036）。
安罗替尼在延长患者PFS方面表现出良好的耐受性和疗效，作为晚期NSCLC的治疗具有相当大的潜力。
Zotero 插件